Lanyi Chen is an Oncology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 24 publications with 213 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
82.1%Statin30.9%Atorvastatin Calcium54%Rosuvastatin Calcium24%Simvastatin22%Part D<11 patientsCalcium channel blocker19.8%Amlodipine Besylate100%Part D≥14 patients+ 3 more classes in this area
Genitourinary & hormones
9.3%alpha-Adrenergic Blocker9.3%Tamsulosin Hcl100%Part D<11 patientsMetabolism & gastrointestinal
8.6%Biguanide (metformin)8.6%Metformin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Molecular characterization and treatment patterns of lung cancer in solid organ transplant (SOT) recipients.
Journal of Clinical Oncology
2026 - Molecular profiling and perioperative management of inflammatory myofibroblastic tumors at a single institution.
Journal of Clinical Oncology
2026 - Impact of genomic subtype on intracranial outcomes in treatment-naive EGFR -mutant NSCLC with osimertinib (IGnITE).
Journal of Clinical Oncology
2026 - Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE)
Journal of Thoracic Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Clerkin, MD
NewYork–Presbyterian Hospital
Marc Richmond, MD
NewYork–Presbyterian Hospital
Shayan Dioun, MD
NewYork–Presbyterian Hospital
Manuel Hidalgo Medina, MD
NewYork–Presbyterian Hospital
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”